Headache最新文献

{"title":"The acute effect of night work-related circadian misalignment on headache episodes: Results from the 1001 nights-cohort.","authors":"Rikke Harmsen, Jakob Møller Hansen, Dagfinn Matre, Anne Emily Saunte Fiehn Arup, Anne Helene Garde, Kirsten Nabe-Nielsen","doi":"10.1111/head.15054","DOIUrl":"10.1111/head.15054","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to investigate the prevalence of headaches on days with night shifts compared with days with day shifts within the same individuals, accounting for work-related psychosocial stressors, physical job demands, and sleep duration and quality. This approach allowed us to isolate the impact of circadian misalignment due to night work from other potential headache triggers.</p><p><strong>Background: </strong>Night work has been suggested to increase the risk of headaches, primarily due to circadian misalignment and disturbed sleep. Most previous studies compare night workers with day workers, but differences in job characteristics and tasks between these groups may introduce bias. To minimize this potential bias, we examined headache occurrence under different working conditions (night vs. day shifts) within the same individuals.</p><p><strong>Methods: </strong>We used data from 14 days of repeated measurements in the 1001 nights-cohort, which includes female employees from the Danish hospital sector. Data were collected from September 2022 to April 2024. Participants completed diaries for 14 consecutive days, providing daily information on working hours, sleep, work-related psychosocial stressors, physical job demands, and headache occurrence (yes/no). Participants with data from at least one day shift and at least one night shift were eligible for inclusion in the analyses. In total, 522 participants contributed 3348 measurement days (1926 day shifts and 1422 night shifts). We estimated prevalence ratios (PRs) for headache occurrence while accounting for repeated measures within individuals and with adjustment for possible confounders (adjusted prevalence ratio [aPR]).</p><p><strong>Results: </strong>Headache was reported on 21.5% of measurement days with day shifts and on 27.9% of measurement days with night shifts. Working a night shift was associated with a significantly higher headache prevalence (aPR, 1.31; 95% confidence interval, 1.13-1.52) compared with day shifts when adjusting for work-related psychosocial stressors, physical job demands, and sleep duration and quality. For consecutive night shifts, the similarly adjusted headache prevalence was highest on the measurement day with the second night shift (aPR, 1.20; 95% confidence interval, 1.02-1.42), using the first night shift as a reference.</p><p><strong>Conclusion: </strong>This study is the first to investigate the headache prevalence when working night shifts compared with day shifts while accounting for work-related psychosocial stressors and physical job demands. Neither these factors, nor shorter sleep duration or lower sleep quality, explained the increased headache prevalence observed when participants worked night shifts. Thus, other (cascading) effects and underlying mechanisms of night work-related circadian misalignment may be the primary drivers of headache in night shift workers.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1554-1564"},"PeriodicalIF":4.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pain Reprocessing Therapy for migraine: A case series.","authors":"Joel N Fishbein, Nathaniel M Schuster, Alpha Anders, Ariel M Portera, Matthew S Herbert","doi":"10.1111/head.15043","DOIUrl":"10.1111/head.15043","url":null,"abstract":"<p><p>Pain Reprocessing Therapy (PRT) is a behavioral intervention that aims to remediate learned threat associations underlying chronic pain. It has shown efficacy in treating chronic low back pain and was explicitly developed to address a broader range of centrally mediated pain conditions. The focus of PRT on learned threat associations dovetails with emerging neurobiological models of migraine, which highlight learned threat associations-nonharmful internal (e.g., hunger, fatigue) or external (e.g., weather changes) cues that are persistently misinterpreted as danger signals-as a modifiable contributor to migraine pathophysiology. Despite its conceptual relevance, PRT has not yet been studied for migraine, a leading cause of disability with an ongoing need for more effective treatments, especially for patients who are refractory to evidence-based treatments. Addressing this gap, we present the first case series on PRT for migraine. We describe three individuals with chronic migraine who engaged in PRT delivered by a physician. All three patients had inadequate response to standard-of-care preventive and acute migraine treatments and presented with complex clinical histories, including non-headache pain comorbidities. PRT sessions (initial visit 60 min; follow-ups 30 min) focused on two key components: (1) education about neuroplastic pain and its relevance to migraine, and (2) guided instruction and daily practice of somatic tracking. Across all three cases, patients experienced large reductions in headache frequency and clinically meaningful improvements in pain intensity and functional outcomes. Case 1 improved from 18 to 25 headache days/month to 3, discontinued cannabis use, and canceled planned interventional treatments. Case 2 improved from 30 headache days/month to 5 and reported greater effectiveness and decreased use of acute medication. Case 3 improved from 30 migraine days/month to 3-4, remained off preventive medication, and reported improvement in migraine and comorbid pelvic and abdominal pain. In all cases, the most substantial gains appeared to follow a shift in pain attribution toward a learned threat association model and daily engagement in somatic tracking, consistent with prior literature on PRT in low back pain. This case series is the first to document the use of PRT for migraine and suggests its potential relevance as a mechanistically informed behavioral intervention for migraine. There is now a need to systematically evaluate PRT for migraine in controlled studies.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1660-1665"},"PeriodicalIF":4.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete-choice experiment.","authors":"Richard B Lipton, Pranav Gandhi, Kelley Myers, Cooper Bussberg, Jonathan Stokes, Stephanie J Nahas","doi":"10.1111/head.14974","DOIUrl":"10.1111/head.14974","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;This study was conducted among participants with episodic migraine, to (i) assess patient preferences for attributes associated with calcitonin gene-related peptide-targeting therapies to prevent migraine and (ii) predict the probability that a real-world patient would prefer an atogepant-like treatment profile over monoclonal antibody-like profiles.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Calcitonin gene-related peptide-targeting therapies have emerged as safe and effective first-line preventive treatments for migraine. Given the expansion of the treatment landscape, it is important to understand what drives treatment choices among patients with migraine. However, few studies have quantified patient preferences for attributes of preventive treatments for migraine.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A discrete-choice experiment survey was administered to adults (aged 18-80 years and &lt;50 years at age of migraine onset) with episodic migraine who were naïve to calcitonin gene-related peptide-targeting therapies between November and December 2020. Respondents were presented with pairs of hypothetical treatment profiles defined by seven attributes with varying levels. Preference weights were used to estimate the conditional relative importance of each attribute and the probability that an average respondent in the sample would prefer an atogepant-like treatment relative to monoclonal antibody-like treatment profiles. No a priori hypotheses were evaluated related to treatment preference.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Across the attributes and levels included in the study, the relative importance estimates revealed that, on average, the two most important changes in treatment attributes were (i) having a treatment with no nausea instead of a treatment with moderate-to-severe nausea and (ii) having a treatment administered by oral pill or tablet instead of a self-injection once every month or intravenous infusion once every 3 months. For example, respondents valued having a treatment administered by daily oral pill instead of by quarterly intravenous infusion ~2.5 times more than avoiding a treatment with mild nausea. The predicted probability that an average respondent in the sample would prefer an oral, once-daily atogepant-like profile was higher than the predicted probability that an average respondent in the sample would prefer a specific monoclonal antibody-like injectable profile (range, 70.9%-85.4%) or a composite profile representing monoclonal antibodies as a class of drugs (range, 70.7%-73.8%), even when efficacy of the monoclonal antibody-like profile was similar to the atogepant-like profile.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Relative importance estimates suggest that, on average, respondents with episodic migraine preferred an oral pill over monthly or quarterly injections and infusions. Respondents also preferred to avoid treatment-related nausea and constipation. The predicted choice probability results further","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1541-1553"},"PeriodicalIF":4.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early nimodipine treatment in reversible cerebral vasoconstriction syndrome: A serial transcranial Doppler study.","authors":"Soohyun Cho, Minjung Seong, Mi Ji Lee","doi":"10.1111/head.14999","DOIUrl":"10.1111/head.14999","url":null,"abstract":"<p><strong>Objectives/background: </strong>Although nimodipine is commonly used to treat reversible cerebral vasoconstriction syndrome (RCVS), its disease-modifying effects are not yet understood. We prospectively investigated the effect of nimodipine and treatment initiation timing on the prevention of worsened vasoconstriction in patients with angiogram-proven RCVS.</p><p><strong>Methods: </strong>In this prospective cohort study, we recruited patients with angiogram-proven RCVS who visited a single headache clinic between June 2019 and November 2021. To evaluate the mean flow velocities (MFVs) of the middle cerebral arteries, patients underwent transcranial Doppler at baseline and were then serially followed up after 10, 20, 30, and 90 days. Oral nimodipine treatment was initiated after the baseline transcranial Doppler study. We estimated the worsening of vasoconstriction using the area of total time spent with MFVs above the baseline value (\"MFV area\").</p><p><strong>Results: </strong>A total of 32 patients (51.5 ± 10.3 years old, 91% female) completed this study. During nimodipine treatment, MFVs gradually decreased in 94% (n = 30/32) of patients (p < 0.001). The MFVs in the early treatment group (<7 days after onset) were lower than the untreated baseline MFVs of the late treatment group (≥7 days) at the same time point after onset (69.8 ± 19.4 vs. 86.1 ± 23.7 cm/s, p = 0.032). Earlier treatment with nimodipine correlated with reduced MFV area (r = 0.37, p = 0.038), and this relationship remained significant after adjustment for covariates (β = 58.46, 95% confidence interval = 2.31-114.62, p = 0.041).</p><p><strong>Conclusion: </strong>Our study shows an independent association between the timing of oral nimodipine administration and exacerbation of cerebral vasoconstriction in patients with RCVS, suggesting that early administration of nimodipine may have a role in mitigating vasoconstriction. A potential disease-modifying role of nimodipine should be tested in future studies using a hypothesis-testing design.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1617-1625"},"PeriodicalIF":4.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144495944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Second-line pharmacological treatment strategies for trigeminal neuralgia: A retrospective comparison of lacosamide, gabapentin and baclofen\".","authors":"Alcántara Montero A","doi":"10.1111/head.15022","DOIUrl":"10.1111/head.15022","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1507-1508"},"PeriodicalIF":4.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"State of the art in the management of migraine-A response to the American College of Physicians migraine preventive treatment guideline.","authors":"Andrew C Charles, Stewart J Tepper, Jessica Ailani","doi":"10.1111/head.15051","DOIUrl":"10.1111/head.15051","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1653-1656"},"PeriodicalIF":4.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The most efficient way for prevention medications selection.","authors":"Pengfei Zhang","doi":"10.1111/head.15048","DOIUrl":"10.1111/head.15048","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1657-1659"},"PeriodicalIF":4.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of new daily persistent headache: A systematic review and meta-analysis with comparison in regard to different age groups, sex, and patient sample settings.","authors":"Maksymilian Osiowski, Dominik Wróbel, Dominik Taterra, Aleksander Osiowski","doi":"10.1111/head.15050","DOIUrl":"10.1111/head.15050","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to synthesize the existing evidence and determine the prevalence of new daily persistent headache (NDPH) in relation to different population settings and age groups, evaluate sex-related patterns, and explore diagnostic challenges.</p><p><strong>Background: </strong>NDPH is a rare primary headache disorder with poorly documented epidemiological data. This condition is characterized by the sudden onset of an unremitting headache that can resemble other chronic phenotypes. The limited recognition in clinical practice and various clinical presentations often contribute to its initial misclassification and delayed diagnosis.</p><p><strong>Methods: </strong>A systematic review and a meta-analysis were conducted by searching Pubmed/Medline, ScienceDirect, and Embase from the inception of each database until April 24, 2025. Pooled prevalence estimates were calculated for general and clinic-based populations, separately for adults and children/adolescents with or without a diagnosis of chronic daily headache whenever possible. Age at onset and sex differences were also analyzed. This study was designed in accordance with the Meta-analyses of Observational Studies in Epidemiology (MOOSE) guidelines. We assessed the risk of bias using the Joanna Briggs Institute Checklist for Studies Reporting Prevalence Data. The protocol of this study was pre-registered on PROSPERO (ID: CRD42024607748).</p><p><strong>Results: </strong>Out of the initial 14,844 entries, 30 studies involving 74,253 individuals qualified for inclusion in this study. According to the critical appraisal tool, 27 articles were assessed as having \"low\" risk of bias, while three articles were rated as having \"moderate\" risk. The prevalence of NDPH was 0.06% (95% confidence interval [CI]: 0.02-0.18) in the general adult population. In patients evaluated for a headache in a headache-oriented clinic, NDPH was present in 1.23% (95% CI: 0.67-2.23, 95% prediction interval [PI]: 0.11%-12.65%; I² = 95.73) of adults and in 2.39% (95% CI: 0.48-11.12) of children. Among those with chronic daily headache, prevalence was 3.91% (95% CI: 2.45-6.18, 95% PI: 0.75%-18.01%) in adults and 19.60% (95% CI: 14.25-26.35, 95% PI: 6.32%-46.82%) in children. Females tended to be affected more frequently, although these differences did not consistently reach statistical significance. The pooled mean age at onset was 40.44 years (95% CI: 24.51-56.38) among adults in the general population, whereas among individuals with chronic daily headache, it was 36.99 years (95% CI: 33.45-40.54) in adults and 10.73 years (95% CI: 10.22-11.24) in children.</p><p><strong>Conclusion: </strong>Our results show that NDPH is a rare headache disorder both in general and in the clinic-based population. Furthermore, NDPH is substantially more frequent in adolescents in comparison to adults, both among patients experiencing any headache and among patients with chronic daily headache.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1641-1652"},"PeriodicalIF":4.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to: Disagreement with Categorization of Clinical Trials included in Treadwell et al. Systematic Review and Meta-Analysis.","authors":"Jonathan R Treadwell, Ilya Ivlev, Benjamin Rouse, Nikhil K Mull, Dawn C Buse","doi":"10.1111/head.15012","DOIUrl":"10.1111/head.15012","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1505-1506"},"PeriodicalIF":4.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors' response to comment on \"Second-line pharmacological treatment strategies for trigeminal neuralgia: A retrospective comparison of lacosamide, gabapentin, and baclofen\".","authors":"Albert Muñoz-Vendrell, Paloma Valín-Villanueva, Raquel Tena-Cucala, Sergio Campoy, Sergio Martínez-Yélamos, Mariano Huerta-Villanueva","doi":"10.1111/head.15033","DOIUrl":"10.1111/head.15033","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1509-1510"},"PeriodicalIF":4.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}